Age-related macular degeneration is a common cause of blindness, but adding some static noise to a patient’s vision can ...
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead ...
Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a ...
A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.
LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...
Researchers have identified distinct biological features linked to a high risk of developing a severe form of age-related ...
Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.
Key opportunities in the ranibizumab market include rising demand due to increased prevalence of eye diseases driven by aging ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results